Skip to main content
NCBI home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1996 Aug 15;24(16):3235–3241. doi: 10.1093/nar/24.16.3235

Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1.

P C Brown 1, J A Silverman 1
PMCID: PMC146062  PMID: 8774906

Abstract

The mdr2 gene encodes a P-glycoprotein that transports phospholipids across the canalicular membrane in hepatocytes. In this report we describe the isolation, sequencing and first functional characterization of the promoter of mdr2. Analysis of 1.6 kb of DNA upstream of the initiation of translation revealed that this sequence has a high GC content, lacks a TATA element and contains a number of putative transcription factor binding sites. We observed that transcription initiates at several sites between -290 and -463 and that this region was critical for promoter activity. Gel mobility shift assays indicated that Sp1 protein binds to a Sp1 consensus site located at -263. Co-expression of Sp1 protein with a reporter construct containing the -263 GC box demonstrated that Sp1 regulates transcription of this promoter. Expression of a non-functional Sp1 protein did not increase transcription from the mdr2 promoter. Mutation of the -263 GC box diminished the response of the promoter to Sp1 protein. Mutation of this site also decreased expression of this promoter in cells which normally express this gene. These data show that Spl has a role in the regulation of mdr2 expression.

Full Text

The Full Text of this article is available as a PDF (153.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer T. K., Tam S. P., Deugau K. V., Deeley R. G. Apolipoprotein C-II mRNA levels in primate liver. Induction by estrogen in the human hepatocarcinoma cell line, HepG2. J Biol Chem. 1985 Feb 10;260(3):1676–1681. [PubMed] [Google Scholar]
  2. Blasband A. J., Rogers K. T., Chen X. R., Azizkhan J. C., Lee D. C. Characterization of the rat transforming growth factor alpha gene and identification of promoter sequences. Mol Cell Biol. 1990 May;10(5):2111–2121. doi: 10.1128/mcb.10.5.2111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boisclair Y. R., Brown A. L., Casola S., Rechler M. M. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem. 1993 Nov 25;268(33):24892–24901. [PubMed] [Google Scholar]
  4. Borst P., Schinkel A. H., Smit J. J., Wagenaar E., Van Deemter L., Smith A. J., Eijdems E. W., Baas F., Zaman G. J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther. 1993 Nov;60(2):289–299. doi: 10.1016/0163-7258(93)90011-2. [DOI] [PubMed] [Google Scholar]
  5. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  6. Brown P. C., Thorgeirsson S. S., Silverman J. A. Cloning and regulation of the rat mdr2 gene. Nucleic Acids Res. 1993 Aug 11;21(16):3885–3891. doi: 10.1093/nar/21.16.3885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen X., Wright K. L., Berkowitz E. A., Azizkhan J. C., Ting J. P., Lee D. C. Protein interactions at Sp1-like sites in the TGF alpha promoter as visualized by in vivo genomic footprinting. Oncogene. 1994 Nov;9(11):3179–3187. [PubMed] [Google Scholar]
  8. Chin K. V., Pastan I., Gottesman M. M. Function and regulation of the human multidrug resistance gene. Adv Cancer Res. 1993;60:157–180. doi: 10.1016/s0065-230x(08)60825-8. [DOI] [PubMed] [Google Scholar]
  9. Courey A. J., Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell. 1988 Dec 2;55(5):887–898. doi: 10.1016/0092-8674(88)90144-4. [DOI] [PubMed] [Google Scholar]
  10. Dusing M. R., Wiginton D. A. Sp1 is essential for both enhancer-mediated and basal activation of the TATA-less human adenosine deaminase promoter. Nucleic Acids Res. 1994 Feb 25;22(4):669–677. doi: 10.1093/nar/22.4.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gant T. W., Schrenk D., Silverman J. A., Thorgeirsson S. S. Requirement for metabolic activation of acetylaminofluorene to induce multidrug gene expression. Environ Health Perspect. 1994 Oct;102 (Suppl 6):209–212. doi: 10.1289/ehp.94102s6209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gant T. W., Silverman J. A., Bisgaard H. C., Burt R. K., Marino P. A., Thorgeirsson S. S. Regulation of 2-acetylaminofluorene-and 3-methylcholanthrene--mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol Carcinog. 1991;4(6):499–509. doi: 10.1002/mc.2940040614. [DOI] [PubMed] [Google Scholar]
  13. Gant T. W., Silverman J. A., Thorgeirsson S. S. Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor. Nucleic Acids Res. 1992 Jun 11;20(11):2841–2846. doi: 10.1093/nar/20.11.2841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gorman C., Padmanabhan R., Howard B. H. High efficiency DNA-mediated transformation of primate cells. Science. 1983 Aug 5;221(4610):551–553. doi: 10.1126/science.6306768. [DOI] [PubMed] [Google Scholar]
  15. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  16. Gros P., Ben Neriah Y. B., Croop J. M., Housman D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986 Oct 23;323(6090):728–731. doi: 10.1038/323728a0. [DOI] [PubMed] [Google Scholar]
  17. Guild B. C., Mulligan R. C., Gros P., Housman D. E. Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1595–1599. doi: 10.1073/pnas.85.5.1595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hill B. A., Brown P. C., Preisegger K. H., Silverman J. A. Regulation of mdr1b gene expression in Fischer, Wistar and Sprague-Dawley rats in vivo and in vitro. Carcinogenesis. 1996 Mar;17(3):451–457. doi: 10.1093/carcin/17.3.451. [DOI] [PubMed] [Google Scholar]
  19. Ince T. A., Scotto K. W. Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells. Gene. 1995 Apr 24;156(2):287–290. doi: 10.1016/0378-1119(94)00907-a. [DOI] [PubMed] [Google Scholar]
  20. Kollmar R., Sukow K. A., Sponagle S. K., Farnham P. J. Start site selection at the TATA-less carbamoyl-phosphate synthase (glutamine-hydrolyzing)/aspartate carbamoyltransferase/dihydroorotase promoter. J Biol Chem. 1994 Jan 21;269(3):2252–2257. [PubMed] [Google Scholar]
  21. Leggett R. W., Armstrong S. A., Barry D., Mueller C. R. Sp1 is phosphorylated and its DNA binding activity down-regulated upon terminal differentiation of the liver. J Biol Chem. 1995 Oct 27;270(43):25879–25884. doi: 10.1074/jbc.270.43.25879. [DOI] [PubMed] [Google Scholar]
  22. Ludwig J., Czaja A. J., Dickson E. R., LaRusso N. F., Wiesner R. H. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver. 1984 Apr;4(2):105–116. doi: 10.1111/j.1600-0676.1984.tb00914.x. [DOI] [PubMed] [Google Scholar]
  23. Mauad T. H., van Nieuwkerk C. M., Dingemans K. P., Smit J. J., Schinkel A. H., Notenboom R. G., van den Bergh Weerman M. A., Verkruisen R. P., Groen A. K., Oude Elferink R. P. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol. 1994 Nov;145(5):1237–1245. [PMC free article] [PubMed] [Google Scholar]
  24. Miltenberger R. J., Farnham P. J., Smith D. E., Stommel J. M., Cornwell M. M. v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1. Cell Growth Differ. 1995 May;6(5):549–556. [PubMed] [Google Scholar]
  25. Nakatsukasa H., Silverman J. A., Gant T. W., Evarts R. P., Thorgeirsson S. S. Expression of multidrug resistance genes in rat liver during regeneration and after carbon tetrachloride intoxication. Hepatology. 1993 Nov;18(5):1202–1207. [PubMed] [Google Scholar]
  26. Nordeen S. K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques. 1988 May;6(5):454–458. [PubMed] [Google Scholar]
  27. Rathmell W. K., Chu G. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. Mol Cell Biol. 1994 Jul;14(7):4741–4748. doi: 10.1128/mcb.14.7.4741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994 Jul 1;77(7):1071–1081. doi: 10.1016/0092-8674(94)90446-4. [DOI] [PubMed] [Google Scholar]
  29. Schinkel A. H., Smit J. J., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A., van der Valk M. A., Robanus-Maandag E. C., te Riele H. P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994 May 20;77(4):491–502. doi: 10.1016/0092-8674(94)90212-7. [DOI] [PubMed] [Google Scholar]
  30. Schrenk D., Gant T. W., Michalke A., Orzechowski A., Silverman J. A., Battula N., Thorgeirsson S. S. Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells. Carcinogenesis. 1994 Nov;15(11):2541–2546. doi: 10.1093/carcin/15.11.2541. [DOI] [PubMed] [Google Scholar]
  31. Silverman J. A., Hill B. A. Characterization of the basal and carcinogen regulatory elements of the rat mdr1b promoter. Mol Carcinog. 1995 May;13(1):50–59. doi: 10.1002/mc.2940130109. [DOI] [PubMed] [Google Scholar]
  32. Silverman J. A., Raunio H., Gant T. W., Thorgeirsson S. S. Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene. 1991 Oct 15;106(2):229–236. doi: 10.1016/0378-1119(91)90203-n. [DOI] [PubMed] [Google Scholar]
  33. Silverman J. A., Thorgeirsson S. S. Regulation and function of the multidrug resistance genes in liver. Prog Liver Dis. 1995;13:101–123. [PubMed] [Google Scholar]
  34. Smit J. J., Mol C. A., van Deemter L., Wagenaar E., Schinkel A. H., Borst P. Characterization of the promoter region of the human MDR3 P-glycoprotein gene. Biochim Biophys Acta. 1995 Mar 14;1261(1):44–56. doi: 10.1016/0167-4781(94)00214-n. [DOI] [PubMed] [Google Scholar]
  35. Smit J. J., Schinkel A. H., Oude Elferink R. P., Groen A. K., Wagenaar E., van Deemter L., Mol C. A., Ottenhoff R., van der Lugt N. M., van Roon M. A. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993 Nov 5;75(3):451–462. doi: 10.1016/0092-8674(93)90380-9. [DOI] [PubMed] [Google Scholar]
  36. Thorgeirsson S. S., Silverman J. A., Gant T. W., Marino P. A. Multidrug resistance gene family and chemical carcinogens. Pharmacol Ther. 1991;49(3):283–292. doi: 10.1016/0163-7258(91)90059-u. [DOI] [PubMed] [Google Scholar]
  37. Zhu Q., Center M. S. Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. Cancer Res. 1994 Aug 15;54(16):4488–4492. [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES